SGS launches GMP-compliant NMR testing for China pharma industry

By AI, Created 3:31 PM UTC, June 03, 2026, /AGP/ – SGS has added GMP-compliant nuclear magnetic resonance testing for pharmaceutical development and manufacturing in China. The service is designed to help drugmakers confirm identity, purity and quality while supporting routine quality control and regulatory confidence.

Why it matters: - The new service gives pharmaceutical manufacturers in China another GMP-compliant tool for identity, purity and quality testing. - NMR can support drug development and manufacturing with detailed molecular analysis without destroying samples. - The launch is aimed at improving product safety, efficacy and regulatory confidence across the pharmaceutical supply chain.

What happened: - SGS expanded its analytical capabilities in China by introducing nuclear magnetic resonance testing for the pharmaceutical industry. - The service covers both drug substances and drug products. - SGS said the expansion supports pharmaceutical manufacturers across China.

The details: - NMR is a non-destructive analytical technique that reveals detailed molecular structures and compositions. - The method complements chromatographic and spectroscopic testing. - The service supports active pharmaceutical ingredient structure confirmation and isomer differentiation. - The service identifies impurities and degradation products down to 0.1% w/w. - The service supports polymorphism analysis for solid-form control. - Quantitative NMR, or qNMR, provides accurate and traceable assay results. - SGS said the service is designed for routine quality control, identity testing, purity assessment and quantitation of synthesized drug substances and raw materials. - SGS said the new capability is cost-effective and high-throughput. - SGS said the expansion reinforces its commitment to innovative, compliant and high-value testing solutions. - A technical brochure is available for stakeholders seeking more information.

Between the lines: - The launch broadens SGS’s role in pharmaceutical testing in a market where compliance and traceability are central to manufacturing decisions. - NMR can add value where manufacturers need deeper structural confirmation or impurity analysis than routine methods may provide. - The emphasis on GMP compliance suggests SGS is targeting regulated development and production work, not just research use.

What’s next: - Stakeholders can download SGS’s technical brochure for more information. - Pharmaceutical manufacturers in China can now evaluate NMR as part of their routine testing and release workflows. - SGS may use the new capability to deepen its offerings for regulated drug development and manufacturing customers in China.